Compare CTW & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 171.9M |
| IPO Year | N/A | 2020 |
| Metric | CTW | BDTX |
|---|---|---|
| Price | $2.47 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 28.9K | ★ 2.0M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.93 |
| 52 Week High | $3.14 | $4.94 |
| Indicator | CTW | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 39.16 |
| Support Level | $1.88 | N/A |
| Resistance Level | $2.68 | $2.47 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 37.97 | 0.28 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.